{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:48:28Z","timestamp":1782262108952,"version":"3.54.5"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T00:00:00Z","timestamp":1779494400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008920","name":"University of Saskatchewan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008920","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Affective Disorders"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jad.2026.122014","type":"journal-article","created":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T06:47:26Z","timestamp":1779518846000},"page":"122014","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Episode duration and severity as predictors of placebo response in major depressive disorder"],"prefix":"10.1016","volume":"411","author":[{"given":"Evyn M.","family":"Peters","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adetunji","family":"Quadri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saba","family":"Aziz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lloyd","family":"Balbuena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.jad.2026.122014_bb0005","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/YIC.0b013e32830cebed","article-title":"Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg\/day for major depressive disorder in a placebo-controlled trial","volume":"23","author":"Boyer","year":"2008","journal-title":"Int. Clin. Psychopharmacol."},{"issue":"3","key":"10.1016\/j.jad.2026.122014_bb0010","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/0165-1781(92)90002-K","article-title":"Clinical features of depressed patients who do and do not improve with placebo","volume":"41","author":"Brown","year":"1992","journal-title":"Psychiatry Res."},{"issue":"5","key":"10.1016\/j.jad.2026.122014_bb0015","doi-asserted-by":"crossref","first-page":"562","DOI":"10.4088\/JCP.13m08978","article-title":"Desvenlafaxine 50 and 100 mg\/d versus placebo for the treatment of major depressive disorder: a phase 4, randomized controlled trial","volume":"76","author":"Clayton","year":"2015","journal-title":"J. Clin. Psychiatry"},{"issue":"5","key":"10.1016\/j.jad.2026.122014_bb0020","doi-asserted-by":"crossref","first-page":"677","DOI":"10.4088\/JCP.v68n0504","article-title":"A double-blind, placebo-controlled study of the efficacy and safety of desvenlafaxine succinate in the treatment of major depressive disorder","volume":"68","author":"DeMartinis","year":"2007","journal-title":"J. Clin. Psychiatry"},{"issue":"2","key":"10.1016\/j.jad.2026.122014_bb0025","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1177\/1536867X1501500203","article-title":"Two-stage individual participant data meta-analysis and generalized forest plots","volume":"15","author":"Fisher","year":"2015","journal-title":"Stata J."},{"issue":"1","key":"10.1016\/j.jad.2026.122014_bb0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/eb-2017-102827","article-title":"Is placebo response in antidepressant trials rising or not? A reanalysis of datasets to conclude this long-lasting controversy","volume":"21","author":"Furukawa","year":"2018","journal-title":"BMJ Ment. Health."},{"issue":"1\u20133","key":"10.1016\/j.jad.2026.122014_bb0035","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jad.2011.06.015","article-title":"The incidence and prevalence of admissions for melancholia in two cohorts (1875\u20131924 and 1995\u20132005)","volume":"134","author":"Harris","year":"2011","journal-title":"J. Affect. Disord."},{"issue":"1","key":"10.1016\/j.jad.2026.122014_bb0040","first-page":"5","article-title":"Efficacy and safety of desvenlafaxine 25 and 50 mg\/day in a randomized, placebo-controlled study of depressed outpatients","volume":"19","author":"Iwata","year":"2013","journal-title":"J. Psychiatr. Res."},{"issue":"2","key":"10.1016\/j.jad.2026.122014_bb0045","first-page":"125","article-title":"Chronicity of depressive episode in relation to antidepressant-placebo response","volume":"4","author":"Khan","year":"1991","journal-title":"Neuropsychopharmacol"},{"issue":"4","key":"10.1016\/j.jad.2026.122014_bb0050","doi-asserted-by":"crossref","first-page":"509","DOI":"10.4088\/JCP.09m05949blu","article-title":"Efficacy of antidepressants for dysthymia: a meta-analysis of placebo-controlled randomized trials","volume":"72","author":"Levkovitz","year":"2011","journal-title":"J. Clin. Psychiatry"},{"issue":"7","key":"10.1016\/j.jad.2026.122014_bb0055","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1185\/03007990802161923","article-title":"Efficacy, safety, and tolerability of desvenlafaxine 50 mg\/day and 100 mg\/day in outpatients with major depressive disorder","volume":"24","author":"Liebowitz","year":"2008","journal-title":"Cur. Med. Res. Opin."},{"issue":"1","key":"10.1016\/j.jad.2026.122014_bb0060","doi-asserted-by":"crossref","DOI":"10.1186\/1471-244X-13-94","article-title":"A double-blind, randomized, placebo-controlled study assessing the efficacy and tolerability of desvenlafaxine 10 and 50 mg\/day in adult outpatients with major depressive disorder","volume":"13","author":"Liebowitz","year":"2013","journal-title":"BMC Psychiatry"},{"issue":"3","key":"10.1016\/j.jad.2026.122014_bb0065","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1185\/03007995.2011.654010","article-title":"Predictors of remission with placebo using an integrated study database from patients with major depressive disorder","volume":"28","author":"Nelson","year":"2012","journal-title":"Cur. Med. Res. Opin."},{"issue":"4","key":"10.1016\/j.jad.2026.122014_bb0070","doi-asserted-by":"crossref","first-page":"456","DOI":"10.4088\/JCP.14r09297","article-title":"The nature of placebo response in clinical studies of major depressive disorder","volume":"76","author":"Papakostas","year":"2015","journal-title":"J. Clin. Psychiatry"},{"issue":"3","key":"10.1016\/j.jad.2026.122014_bb0075","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/JCP.0000000000001393","article-title":"Melancholic features in bipolar depression and response to lamotrigine: a pooled analysis of five randomized placebo-controlled trials","volume":"41","author":"Peters","year":"2021","journal-title":"J. Clin. Psychopharmacol."},{"issue":"11","key":"10.1016\/j.jad.2026.122014_bb0080","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1176\/ajp.150.11.1618","article-title":"The DST as a predictor of outcome in depression: a meta-analysis","volume":"150","author":"Ribeiro","year":"1993","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2026.122014_bb0085","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.jad.2020.01.139","article-title":"Melancholic versus nonmelancholic major depression compared","volume":"266","author":"Tondo","year":"2020","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2026.122014_bb0090","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/j.clinthera.2009.07.006","article-title":"Desvenlafaxine 50 and 100 mg\/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies","volume":"31","author":"Tourian","year":"2009","journal-title":"Clin. Ther."},{"key":"10.1016\/j.jad.2026.122014_bb0095","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.psychres.2018.03.088","article-title":"A quantitative review on outcome-to-antidepressants in melancholic unipolar depression","volume":"265","author":"Valerio","year":"2018","journal-title":"Psychiatry Res."},{"issue":"12","key":"10.1016\/j.jad.2026.122014_bb0100","doi-asserted-by":"crossref","first-page":"B49","DOI":"10.1016\/j.clinthera.2011.11.019","article-title":"Solving the antidepressant efficacy question: effect sizes in major depressive disorder","volume":"33","author":"V\u00f6hringer","year":"2011","journal-title":"Clin. Ther."}],"container-title":["Journal of Affective Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032726008669?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032726008669?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:32:37Z","timestamp":1782261157000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165032726008669"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":20,"alternative-id":["S0165032726008669"],"URL":"https:\/\/doi.org\/10.1016\/j.jad.2026.122014","relation":{},"ISSN":["0165-0327"],"issn-type":[{"value":"0165-0327","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Episode duration and severity as predictors of placebo response in major depressive disorder","name":"articletitle","label":"Article Title"},{"value":"Journal of Affective Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jad.2026.122014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"122014"}}